AstraZeneca Outlines Two-year Development, Debt Reduction Strategy
This article was originally published in The Pink Sheet Daily
Executive Summary
Anglo-Swiss pharma reports first quarter sales increases for Seroquel and Crestor; Nexium declines.
You may also be interested in...
Ranbaxy Will Begin U.S. Sales Of Generic Nexium In 2014 Under Deal Ending Patent Litigation
Deal demonstrates strength of AstraZeneca’s patents, analyst says.
AstraZeneca Submits Seroquel XR sNDA For Major Depressive Disorder
Firm looks to expand $4 billion franchise into lucrative MDD market.
AstraZeneca Tries For Seroquel XR Approvals In Europe
Firm bids to expand $4 billion franchise into bipolar disorder’s manic and depressive episodes, as patent challenges loom.